| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
(E)-4-Hydroxytamoxifen (Afimoxifene) is the less active isomer of 4-Hydroxytamoxifen. 4-Hydroxytamoxifen is the active metabolite of tamoxifen which is an anticancer drug and a SERM/selective estrogen receptor modulator.
| Targets |
Estrogen Receptor/ERR
|
|---|---|
| ln Vitro |
Afimoxifene is a tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
It is absorbed after local application. |
| Additional Infomation |
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol is a stilbene compound. Afimoxifene (4-hydroxytamoxifen, trade name TamoGel) is a novel estrogen inhibitor currently under investigation for the treatment of various estrogen-dependent disorders, including cyclical breast pain and gynecomastia. TamoGel is formulated using enhanced hydroalcoholic gel (EHG) technology. This technology enables transdermal drug delivery, allowing for drug delivery that cannot be taken orally. It was developed by Ascent Therapeutics. Afimoxifene is a metabolite of tamoxifen and has both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for estrogen receptors than tamoxifen and acts as an antagonist in breast cancer cells. Indications: For the treatment of cyclical breast pain, fibrocystic breast disease, breast disease, gynecomastia, and keloids.
Mechanism of Action Afimoxifene binds to the estrogen receptor (ER), inducing a conformational change in the receptor. This leads to the blockade or alteration of estrogen-dependent gene expression. Afimoxifene binds to the estrogen receptor (ER), inducing a conformational change in the receptor. This results in the blockade or alteration of estrogen-dependent gene expression. |
| Molecular Formula |
C26H29NO2
|
|---|---|
| Molecular Weight |
387.51396
|
| Exact Mass |
387.22
|
| Elemental Analysis |
C, 80.59; H, 7.54; N, 3.61; O, 8.26
|
| CAS # |
174592-47-3
|
| Related CAS # |
4-Hydroxytamoxifen;68047-06-3;(E/Z)-4-Hydroxytamoxifen;68392-35-8; 174592-47-3 (E-isomer)
|
| PubChem CID |
5352135
|
| Appearance |
White to off-white solid powder
|
| Density |
1.092g/cm3
|
| Boiling Point |
514.4ºC at 760 mmHg
|
| Flash Point |
264.9ºC
|
| Vapour Pressure |
3.35E-11mmHg at 25°C
|
| Index of Refraction |
1.596
|
| LogP |
5.701
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
493
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=C(C=C1)/C(C2=CC=C(C=C2)OCCN(C)C)=C(CC)\C3=CC=CC=C3
|
| InChi Key |
TXUZVZSFRXZGTL-OCEACIFDSA-N
|
| InChi Code |
InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25+
|
| Chemical Name |
4-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
|
| Synonyms |
Afimoxifene; Afimoxifene, E-isomer; 68392-35-8; E-4-Hydroxytamoxifen; AKE3PH0IML; CHEMBL279301; (E)-4-Hydroxytamoxifen; cis-4-Hydroxytamoxifen; 4-((1E)-1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~32.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5806 mL | 12.9029 mL | 25.8058 mL | |
| 5 mM | 0.5161 mL | 2.5806 mL | 5.1612 mL | |
| 10 mM | 0.2581 mL | 1.2903 mL | 2.5806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
